{
    "nctId": "NCT02854618",
    "briefTitle": "Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus",
    "officialTitle": "Study of the Immune Response T Anti-tumoral Cluster of Differentiation 4 (CD4) for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 112,
    "primaryOutcomeMeasure": "level of the spontaneous anti-telomerase response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* patients eligible for a treatment by everolimus in association with the exemestane\n* Performance status of 0,1 or 2 according to the WHO\n* Patients affected of a breast cancer advanced and\\\\or metastatic HER2 negative expressing the hormonal receptor RH +\n* menopausal Patients\n\nExclusion Criteria:\n\n* Psychiatric disease compromising the understanding of the information or the realization of the study\n* Vulnerable people according to the law (minors, adults under protection, private persons of freedom)\n* Histories of cancer in 5 years preceding the diagnosis (except breast cancer, squamous-cell)\n* Not menopausal women\n* Unaffiliated people to the Social Security\n* People being for the period of exclusion from another study\n* Hypersensitivity in the active substance, in the other by-products of the rapamycin or in one of the excipients.\n* Symptomatic visceral achievement\n* Legal incapacity or limited legal capacity",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}